Related Experiment Video
Updated: Jul 10, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
[Aberrant methylation of tumor suppressor genes in renal cell carcinoma]
Qian Zhang1, Jie Jin, Qian Tao
1Department of Urology, Institute of Urology, The First Hospital, Peking University, Beijing, 100034, PR China.
Abstract:
Promoter CpG methylation is a major epigenetic mechanism to inactivate the functions of tumor suppressor genes (TSG), in addition to genetic mechanism (point mutation and deletion), plays important roles in the pathogenesis of various tumors. Renal cell carcinoma (RCC) is a malignant tumor with poor prognosis, in which aberrant methylation of TSGs has also been widely reported. Most RCC patients are presented with advanced disease because early stage RCC does not have apparent symptoms. The detection of TSG methylation might provide new specific biomarkers for early non-invasive diagnosis of this disease. Because RCC is generally insensitive to conventional chemotherapy and radiotherapy, using epigenetic agents, such as azacytidine, to modulate the activities of DNA methyltransferases and reverse the methylation status of TSGs might be an attractive strategy for future treatment of RCC, which could be combined with conventional therapies. We reviewed recent advances in the research on TSG methylation in RCC, summarized the methylation profile of RCC-related genes, including HOXB13, HAI2/SPINT2, CDH1 and CTNNG/JUP, and discussed the clinical significance of aberrant CpG methylation for the diagnosis and treatment of RCC.
Insights
Promoter CpG methylation inactivates tumor suppressor genes (TSGs) in renal cell carcinoma (RCC). Detecting TSG methylation offers potential biomarkers for early RCC diagnosis and novel epigenetic treatment strategies.
Area of Science:
- Epigenetics
- Molecular Oncology
Context:
- Promoter CpG methylation is a key epigenetic mechanism silencing tumor suppressor genes (TSGs).
- Renal cell carcinoma (RCC) is a malignancy with poor prognosis, often diagnosed at advanced stages due to asymptomatic early development.
- Aberrant methylation of TSGs is frequently observed in RCC pathogenesis.
Purpose:
- To review recent advances in research on TSG methylation in RCC.
- To summarize the methylation profile of RCC-associated genes.
- To discuss the clinical significance of aberrant CpG methylation in RCC diagnosis and treatment.
Summary:
- This review focuses on promoter CpG methylation as a mechanism for TSG inactivation in various cancers, particularly RCC.
- Specific RCC-related genes with altered methylation patterns, including HOXB13, HAI2/SPINT2, CDH1, and CTNNG/JUP, are highlighted.
- Aberrant methylation is discussed as a potential biomarker for early, non-invasive RCC detection and as a target for epigenetic therapies.
Impact:
- TSG methylation detection may yield novel biomarkers for early RCC diagnosis.
- Epigenetic agents targeting DNA methyltransferases could offer new therapeutic strategies for RCC, potentially combined with conventional treatments.
- Understanding TSG methylation profiles is crucial for advancing RCC diagnostics and therapeutics.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
